140 related articles for article (PubMed ID: 38294142)
1. 2-Deoxyglucose and hydroxychloroquine HPLC-MS-MS analytical methods and pharmacokinetic interactions after oral co-administration in male rats.
Sun D; Kim S; Karelia D; Deng Y; Jiang C; Lü J
Pharmacol Res Perspect; 2024 Feb; 12(1):e1173. PubMed ID: 38294142
[TBL] [Abstract][Full Text] [Related]
2. 2-Deoxyglucose and hydroxychloroquine HPLC-MS-MS analytical methods and pharmacokinetic interactions after oral co-administration in male rats.
Sun D; Kim S; Karelia D; Deng Y; Jiang C; Lü J
Res Sq; 2023 Mar; ():. PubMed ID: 36993275
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.
Carmichael SJ; Beal J; Day RO; Tett SE
J Rheumatol; 2002 Oct; 29(10):2077-83. PubMed ID: 12375315
[TBL] [Abstract][Full Text] [Related]
4. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis.
Carmichael SJ; Charles B; Tett SE
Ther Drug Monit; 2003 Dec; 25(6):671-81. PubMed ID: 14639053
[TBL] [Abstract][Full Text] [Related]
6. Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood.
Austin D; John C; Hunt BJ; Carling RS
Clin Chem Lab Med; 2020 Sep; 58(12):2047-2061. PubMed ID: 32915766
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR.
Dongre VG; Ghugare PD; Karmuse P; Singh D; Jadhav A; Kumar A
J Pharm Biomed Anal; 2009 May; 49(4):873-9. PubMed ID: 19201565
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
Zahr N; Urien S; Llopis B; Pourcher V; Paccoud O; Bleibtreu A; Mayaux J; Gandjbakhch E; Hekimian G; Combes A; Benveniste O; Saadoun D; Allenbach Y; Pinna B; Cacoub P; Funck-Brentano C; Salem JE
Therapie; 2021; 76(4):285-295. PubMed ID: 33558079
[TBL] [Abstract][Full Text] [Related]
9. In Vitro and In Vivo Evaluation of Two Hydroxychloroquine Tablet Formulations: HPLC Assay Development.
Emami J; Kazemi M; Salehi A
J Chromatogr Sci; 2021 Jan; 59(1):71-78. PubMed ID: 33089870
[TBL] [Abstract][Full Text] [Related]
10. Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method.
Liu Q; Bi G; Chen G; Guo X; Tu S; Tong X; Xu M; Liu M; Wang B; Jiang H; Wang J; Li H; Wang K; Liu D; Song C
Front Pharmacol; 2020; 11():602880. PubMed ID: 33519466
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
Morita S; Takahashi T; Yoshida Y; Yokota N
Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects.
Song M; Gao X; Hang TJ; Wen AD
Curr Ther Res Clin Exp; 2009 Jun; 70(3):228-39. PubMed ID: 24683233
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of bitopertin, a selective GlyT
Frouni I; Bédard D; Bourgeois-Cayer É; Hamadjida A; Gaudette F; Beaudry F; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1053-1060. PubMed ID: 36633618
[TBL] [Abstract][Full Text] [Related]
14. UHPLC-MS/MS Method for Determination of Hydroxychloroquine and Its Main Metabolites in Oral Fluid and Whole Blood for Therapeutic Drug Monitoring.
Duarte NJC; Kupa LVK; Ferreira-Filho JCR; Fontoura N; Chalom MY; Romano P; Ebner PAR; Silva CAA; Carvalho VM; Bonfá E
J Appl Lab Med; 2021 Jul; 6(4):868-880. PubMed ID: 33907815
[TBL] [Abstract][Full Text] [Related]
15. Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Zou JJ; Bian XJ; Ding L; Zhu YB; Fan HW; Xiao DW
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(1):151-7. PubMed ID: 18069077
[TBL] [Abstract][Full Text] [Related]
16. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects.
Ducharme J; Fieger H; Ducharme MP; Khalil SK; Wainer IW
Br J Clin Pharmacol; 1995 Aug; 40(2):127-33. PubMed ID: 8562294
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
[TBL] [Abstract][Full Text] [Related]
18. [Interaction between atorvastatin and voriconazole in rat plasma: a HPLC-MS/MS-based study].
Lü B; Xun T; Wu S; Zhan X; Rong Y; Zhang Q; Yang X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):337-343. PubMed ID: 31068304
[TBL] [Abstract][Full Text] [Related]
19. Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial.
Stoll F; Blank A; Mikus G; Czock D; Foerster KI; Hermann S; Häußler K; Muhareb A; Hummler S; Weiss J; Burhenne J; Haefeli WE
Trials; 2020 Jun; 21(1):584. PubMed ID: 32600363
[TBL] [Abstract][Full Text] [Related]
20. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.
Tai TT; Wu TJ; Wu HD; Tsai YC; Wang HT; Wang AM; Shih SF; Chen YC
Clin Transl Sci; 2021 Jan; 14(1):132-136. PubMed ID: 33135382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
